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ABSTRACT 
Several flaviviruses, such as the yellow fever virus and the dengue virus cause severe and 
potentially lethal infection in man. Following up on our initial hit 3’,5’-bistritylated uridine 1, 
a series of alkylated nucleoside analogues were synthesized and evaluated for their in vitro 
antiviral activities against dengue fever virus and yellow fever virus. Hereto, alkyl and aryl 
groups were attached at various positions of the sugar ring combined with subtle variation of 
the heterocyclic base. Among the new series of derivatives, 3’,5’-di-O-trityl-5-fluoro-2’-
deoxyuridine (39) was the most efficient in this series and inhibited both yellow fever virus and 
dengue virus replication with a 50% effective concentration (EC50) of ~ 1 µg/mL without 
considerable cytotoxicity. The other fluorinated derivatives proved more toxic. Almost all 
diphenylmethylated pyrimidine nucleosides with 3’,5’-di-O-benzhydryl-2’-deoxyuridine (50) 
as the example were endowed with strong cytotoxic effects down to 1 µg/mL. 
 
 
  
 
 
 
 
 
1. Introduction 
The genus Flavivirus comprises several important human pathogens including the tick-borne 
encephalitis virus, the West Nile virus, the dengue fever virus (DENV) and the yellow fever 
virus (YFV) [1, 2]. Most Flavivirus are transmitted to humans by mosquitoes. Each year an 
estimated 360 million people living in tropical and subtropical regions become infected with 
the DENV of which ~ 96 million develop disease [3]. Approximately 500,000 of the infected 
individuals progress to dengue hemorrhagic fever, leading each year to 22,000 deaths [4-7]. 
With increasing levels of international travel, urbanization and population growth, incidences 
of the DENV illness have increased by 30-fold in the past 50 years. Even though dengue is the 
fastest progressing vector-borne disease worldwide, there is neither vaccine nor an antiviral 
drug available till date. There are an estimated 200,000 cases of yellow fever, of which 30,000 
lead to death, worldwide each year. The virus is endemic in tropical areas of Africa and Latin 
America, with a combined population of over 900 million people [8, 9]. Although a highly 
effective and safe vaccine (17D) is available [10], many people do not get vaccinated, primarily 
because a cold chain is needed for this live- attenuated vaccine. An antiviral drug would prove 
useful for treating the severe infections that may occur in the non-vaccinated, especially during 
epidemics. A most common strategy for developing an antiviral drug is the high-throughput 
screening of large compound libraries in vitro to identify some hit molecules. This is further 
followed by a hit-optimization process. Previous efforts in our group lead to discovery of 3’,5’-
bistritylated uridine 1 (Fig. 1) as a potential inhibitor of flavivirus replication [11, 12]. The 
finding of this lipophilic structure being endowed with high antiviral activity for flaviviruses 
 
  
 
 
 
 
 
stimulated the interest for further structure-activity research. In view of previous results and the 
lack of activity for tritylated purines and for cytidine derivatives, only some uracil analogues 
were considered for further evaluation, being the 5-methyl, N3,5-dimethyl, and 5-fluorouracil 
derivatives, with 5-chlorouracil having been studied before [11]. In addition, substitution of the 
trityl moieties was investigated, as for drug development purposes a less lipophilic structure is 
warranted. We therefore synthesized and tested a series of compounds which were less 
hydrophobic than the initial lead. Hereto, a series of close analogues were prepared in which 
different groups were substituted at the 2’-, 3’- and 5’- position of nucleosides in an effort to 
set a structure-activity relationship (SAR). We here report on this series of nucleoside analogues 
of which some have shown to provide weak inhibition for in vitro DENV and/or YFV 
replication. Unfortunately we have not been able to find suitable substitutions for the trityl 
moieties without causing toxicity or without serious loss of the inhibitory activity.  
 
2. Results and Discussion 
2.1. Synthetic aspects 
Considerable attention in the past has been directed towards the synthesis of nucleoside 
analogues inhibiting the DNA or RNA polymerization process in the hope of discovering new 
selective and more effective antivirals. Following up on the lead compound 1 [11], an additional 
series of tritylated as well as diphenylmethylated uridine and thymidine derivatives was 
envisaged. Likewise, in an effort to substitute for the large trityl moieties in the lead compound, 
 
  
 
 
 
 
 
a series of thymidine analogues carrying different lipophilic moieties at their 3’- and 5’-
hydroxyl position were prepared in an effort to further delineate the SAR properties. The 
chemistry in general is straightforward and the reaction sequences for assembly of the target 
compounds are illustrated in Fig. 2-4. 
In a first strategy, N3-methylation of thymidine has been carried out using methyl iodide 
and potassium carbonate in dry DMF to obtain intermediate 5 in 81% yield [13]. Subsequent 
mono- or bistritylation provided the compounds 6, 9 and 10 (see Fig. 2 for reaction conditions). 
Analogously, thymidine was tritylated affording 17, 20 and 21, respectively (Fig. 2), and 5-
fluoro-2’-deoxyuridine and 5-fluorouridine gave the congeners 38-39 and 41-43, respectively 
following the reaction conditions as shown in Fig. 3. Preparation of these respective tritylated 
derivatives allowed evaluation of the antiflavivirus activity and examination of the role of the 
heterocyclic moiety herein, using thymine, N3-methyl thymine or 5-fluorouracil as the 
heterocyclic base while preserving the hydrophobic tritylated sugar part. Exploring further the 
3D space around the base moiety, the necessity for the lactam moiety was verified. Hereto, a 
triazolo intermediate was used to obtain the O4-methylated analogue 35 instead of the N3-
methyl thymidine (5) which is obtained by direct alkylation (Fig. 4). Prior trimethylsilyl 
protection was accomplished with TMS chloride and triethylamine in acetonitrile at room 
temperature, followed by phosphorus oxychloride promoted introduction of the triazole moiety 
[14]. This method of choice has become very widely used in nucleoside research. Acetic acid-
methanol (1:4 v/v) was added to the residue, and the resulting solution was allowed to stand at 
room temperature for 4.5 h to accomplish trimethylsilyl deprotection. The intermediate 34 was 
 
  
 
 
 
 
 
allowed to react with sodium methoxide in methanol at ambient temperature to afford 
unprotected O4-methyl thymidine (35) [14]. Some starting thymidine however was recovered 
indicating the labiality of the methoxy substituent. The methylated product was purified by 
column chromatography in 60% yield and was expected to be a valuable intermediate in the 
preparation of many key target compounds. However, upon tritylation at elevated temperatures, 
the O4-methyl moiety was cleaved resulting into formation of the known 3’,5’ di-O-
tritylthymidine (21) (Fig. 4). 
Furthermore, the hydroxyl groups in compounds 4 and 5 were alkylated under different 
conditions depending on the moiety to be introduced. Small groups like methyl, benzyl and 
acetyl were easily introduced, but likewise bulky groupings like different trialkylsilyl 
fluorenylmethyloxycarbonyl (Fmoc), adamantyl and long chain alkyl moieties were attached at 
the 3’- and 5’-positions following standard procedures to obtain either mono- or di-substituted 
thymidine derivatives 6-33 (for reaction conditions see Fig. 2). 
Finally, the trityl moieties could be substituted by the less crowded diphenylmethyl group, 
which however is less straightforward to introduce. During this work, a convenient and 
effective method for synthesis of the diphenylmethyl ethers of several nucleosides has been 
developed with the aid of palladium (II) chloride as the catalyst [15]. Hereto, we allowed the 
respective nucleoside to react with diphenylmethanol (DPM-OH) in dichloroethane (DCE) in 
presence of 0.2 equivalents of PdCl2 at 85 ºC overnight (Fig. 5).  
 
2.2. Assessment of the antiviral activity 
 
  
 
 
 
 
 
The previously reported lipophilic uridine analogues 3’,5’-bistrityl uridine 1 and 2’,5’-
bistrityl uridine 2 exert selective inhibition of in vitro DENV and YFV replication [11, 12]. 
Compound 2 inhibited YFV replication with an EC50 of 1.2 µg/mL (1.65 µM) with calculated 
selectivity index (SI) of around 80. However, the molecule proved less potent against DENV 
(SI of ~3). The regioisomer 1 proved to be endowed with more potent activity against both 
viruses with EC50 of 1.0 µg/mL (1.37 µM) and SI of >85 for YFV inhibition. This molecule 
also proved less potent against DENV (SI of ~5). The most active analogue in this series 2’,5’-
bistrityl-5-chlorouridine 3 had EC50 of 0.75 µg/mL (1.0 µM) resulting in SI of >90. On the 
other hand, the monotritylated analogue proved markedly more toxic. Our efforts therefore were 
directed towards synthesising a series of nucleoside derivatives with either substitutions of the 
base moiety, or substituting for the large and very hydrophobic triphenylmethyl groups at the 
sugar part. 
Our efforts to understand the structure –activity relationship of the lead molecules started 
with substitution of hydrogen at the 5-position of the base moiety with fluorine. The unique 
properties of fluorine have led to its widespread application in drug design as an isoster for 
hydrogen. Early applications of the exchange of H by F focused on the region-specific 
deployment of fluorine to interfere with metabolic processes, a tactic that relies on the powerful 
electron withdrawing properties of F and the strength of the C-F. The latter is also known to be 
chemically inert under most biological conditions [16-20]. 
 
  
 
 
 
 
 
Table 1 reports on the DENV and YFV antiviral activities and cellular toxicities of 
respectively tritylated, diphenylmethylated and some benzylated nucleoside analogues. The 
results for some tritylated analogues were reported before and are included here for comparative 
purposes [11, 12]. Upon analysis one notices that the results for the tritylated 5-fluorouridine 
congeners largely correspond with those for uridine with strong YFV inhibition for the 2’,5’-
bistrityl derivative 42 (EC50 1.1 µg/mL) and its 3’,5’ congener 43 (EC50 0.43 µg/mL; CC50 4.4 
µg/mL). Despite the strong antiviral effect, the enhanced cellular toxicity renders both 
compounds with a reduced selectivity index (SI). The bistritylated 5-fluoro-2’-deoxyuridine 39 
however retains analogous anti-YFV activity and cellular toxicity (EC50 1.05 µg/mL; CC50 >50 
µg/mL) compared to its 2’-deoxyuridine congener, preserving a strong SI of >47.  5-
Fluorination of uracil therefore does not provide an advantage, keeping in mind the potential in 
vivo cleavage of glycosidic bonds, yielding the anticancer thymidylate synthase inhibitor 5-
fluorouracil [21]. In analogy with the uridine series, the 2’,5’-bistrityl derivative 42 did not 
display inhibitory properties against proliferation of DENV, while the 3’,5’-bistrityl congeners 
39 and 43 displayed EC50 values in the micromolar range with a SI of >41 for the 5-fluoro-2’-
deoxyuridine analogue 39. The bistritylated N3-methylthymidine analogue 10 however lost all 
of its antiviral and toxic activity, except for the toxic effect of the 5’-monotritylated analogue 6 
displaying a CC50 of 5 µg/mL. The obtained inhibitory activities should be placed in perspective 
with recent results obtained for some reference compounds as highlighted in Table 1. Herein, 
the cytidine analogue 2’-C-methylcytidine in our hands performs very consistently and inhibits 
 
  
 
 
 
 
 
DENV replication with an EC50 of around 10 µM. Valopicitabine, a prodrug of this anti-HCV 
reagent was first described by Gosselin et al. [22] and was reported being active as well against 
flaviviruses. Favipiravir (T705) on the other hand is weakly inhibitory for YFV [23] while the 
helicase inhibitor ivermectin is a very potent inhibitor of flavivirus replication especially YFV 
[24], but performs weaker for in vitro inhibition of DENV. 
In an effort to reduce the lipophilicity, we substituted both trityl moieties in 1 and 2 with 
the benzhydryl group. We also prepared the 2’,3’,5’- trisbenzhydryl derivative which will have 
analogous lipophilicity as the bistrityl derivatives but the orientation of the 6 phenyl rings in 
space being different. In parallel other nucleosides with a 5-fluoro or a 5-methyl substituent at 
the base moiety were alkylated with benzhydryl group and their activities were determined 
against YFV. Remarkably, most of these diphenylmethylated analogues (44-52) are devoid of 
antiviral effects, but display strong cellular toxicity as compared to the trityl derivatives (Table 
1). Toxicities (CC50 values) in general are around 1-2 µg/mL and deserve further attention. Two 
notable exceptions are found in the 5-fluorouridine series where the 2’,5’-bisalkylated analogue 
47 displays an equal antiviral effect (EC50 1.15 µg/mL or 2 µM) and the peralkylated derivative 
49 surprisingly is much less toxic rendering the compound with a SI of 12.5 (EC50 4 µg/mL; 
CC50 >50 µg/mL). 
Finally, for the perbenzylated compounds we did find marginal cellular toxicity 
(compounds 14 and 24), while all other evaluated compounds proved devoid of antiviral activity 
and of cellular toxicity (not shown). The mixed antiviral results obtained so far, render a clear 
 
  
 
 
 
 
 
structure-activity relationship difficult and compromise further study of the tritylated 
nucleoside analogues as anti-YFV compounds, unless a mutant resistant to one of the antiviral 
active tritylated analogues could be grown. In spite of numerous efforts, up to now such mutants 
could not be generated. 
 
3. Conclusion 
A large series of either alkylated, silylated or acylated pyrimidine nucleoside analogues was 
synthesized and evaluated, primarily for their anti-YFV activity. Fluorination of the base 
moiety as in 2’,5’ (42) and 3’,5’-bistritylated 5-fluorouridine (43) preserved the antiviral 
potential but rendered the compounds more toxic compared to their uridine congeners, thus 
reducing the SI. Only with bistritylated 5’-fluoro-2’-deoxyuridine (39) the cellular toxicity was 
reduced and with an EC50 for YFV of 1.05 µg/mL (1.45 µM), an SI of around or above 50 was 
obtained. Pyrimidine nucleosides decorated with diphenylmethyl moieties proved surprisingly 
toxic to cells and in general displayed CC50 values of around 1-2 µg/mL, worthwhile to study 
further. All other synthesized analogues proved devoid of activity. 
 
4. Materials and Methods  
4.1. General synthetic procedures 
Starting nucleosides were obtained from ACROS. All other chemicals were provided by 
Aldrich or ACROS and were of the highest quality. 1H and 13C NMR spectra were determined 
 
  
 
 
 
 
 
with a 300 MHz Varian Gemini apparatus with tetramethylsilane as internal standard for the 1H 
NMR spectra (s = singlet, d = doublet, dd = double doublet, t = triplet, br. s = broad signal, br. 
d = broad doublet, m = multiplet) and the solvent signal – DMSO-d6 (δ =39.6 ppm) or CDCl3 
(δ =76.9 ppm) – for the 13C NMR spectra. Exact mass measurements were performed with a 
quadrupole/orthogonal acceleration time-of-flight tandem mass spectrometer (qTOF2, 
Micromass, Manchester, UK) fitted with a standard electrospray ionization (ESI) interface. All 
solvents were carefully dried or bought as such. Detailed procedures can be found in the 
supplementary file. 
4.2. Alkylated thymidine analogues 
4.2.1 N3-methyl-thymidine (5) [25, 26].  Thymidine (4, 500 mg, 2.06 mmol) was dissolved in 
dry DMF (10 mL) in a 50 ml round bottom flask to give a colourless solution under argon 
atmosphere. Potassium carbonate (856 mg, 6.19 mmol) and methyl iodide (321 µL, 5.16 mmol) 
were added to the reaction mixture. The reaction was sonicated for 2 h at 55 °C and was 
monitored by TLC in 10% MeOH/ CH2Cl2. After 2 h the DMF was evaporated and diluted 
with 20 mL CH2Cl2. The crude product was purified by column chromatography and was eluted 
with CH2Cl2 followed by 10%MeOH/ CH2Cl2 to give 430 mg (81%) of  the desired compound 
5. 1H NMR (MeOD): δ 7.76 (s, 1H), 6.19 (t, 1H), 5.26(s, 1H), 5.05(s, 1H), 4.23 (s, 1H), 3.77 
(s, 1H), 3.39-3.62(m, 2H), 3.16 (s, 3H), 2.08-2.10 (m, 2H), 1.81 (s, 3H). 13C NMR (75MHz, 
MeOD) δ 163.0, 150.7, 134.6, 108.4, 87.5, 85.0, 70.4, 61.4, 39.8, 27.6, 13.1. HRMS (EI+): m/z 
for [C11H16N2O5Na]+ calcd. 279.0952; found 279.0957. 
 
  
 
 
 
 
 
4.2.2 N3-methyl-5’-O-trityl-thymidine (6).  N-methyl-thymidine (5, 100 mg, 0.39 mmol) was 
evaporated 3 times with 5 mL of anhydrous pyridine and dissolved in 2mL of dry pyridine. 
Tritylchloride (131 mg, 0.468 mmol) was added and a red colour was formed. The mixture was 
stirred at 80 °C under argon atmosphere and the reaction progress was monitored using TLC. 
After 18h, the mixture was cooled to room temperature, quenched with 1.5mL of MeOH and 
stirred for 30 min. The mixture was evaporated to dryness. The obtained crude compound was 
purified by column chromatography (CH2Cl2/MeOH, 95:5) to obtain 165 mg (84%) of 6. TLC 
(CH2Cl2/MeOH, 9:1): Rf = 0.90. 1H NMR (500MHz, MeOD): δ 7.71 (s, 1H), 7.44 (d, 6H, J = 
7.40 Hz), 7.33-7.25 (m, 9H), 6.34 (t, 1H, J = 6.71 Hz, H-1’), 4.56-4.51 (m, 1H, H-3’), 4.04-
3.99 (m, 1H, H-4’), 3.44-3.34 (m, 2H, H-5’, H-5’’), 3.29 (s, 3H, N-CH3), 2.35 (t, 2H, J = 5.50 
Hz, H-2’,  H-2’’), 1.46 (s, 3H, 5-CH3). 13C NMR (125MHz, MeOD) δ 165.6 (C-4), 152.5 (C-
2), 145.0 , 135.8 (C-6), 129.9 , 129.0 , 124.5 , 110.6 (C-5), 88.6, 87.8 (C-4’), 87.2 (C-1’), 72.5 
(C-3’), 65.0 (C-5’), 41.6 (C-2’), 28.2 (N-CH3), 12.8(5-CH3). HRMS (EI+): m/z for 
[C30H30N2O5Na]+ calcd. 521.2053; found 521.2043. 
4.2.3. 5’-O-benzoyl-N3-methyl-thymidine (7). N-methyl-thymidine (5, 100 mg, 0.41 mmol) was 
evaporated 3 times with 5 mL of anhydrous pyridine and was dissolved in 2 mL of anhydrous 
pyridine. Reaction was cooled at 0 °C and benzoyl chloride (51 µL, 0.43 mmol) was added. 
The mixture was stirred for 2 h under argon atmosphere. Reaction progress was monitored using 
TLC. The mixture was evaporated to dryness. The obtained crude compound was purified by 
column chromatography (CH2Cl2/MeOH, 95:5) to obtain 125 mg (85%) of 7. TLC 
 
  
 
 
 
 
 
(CH2Cl2/MeOH, 9:1): Rf = 0.60. 1H NMR (500 MHz, MeOD): δ 8.04-8.02 (m, 2H), 7.64-7.61 
(m, 1H), 7.51-7.47 (m, 2H), 7.47-7.44 (m, 1H), 6.30-6.28 (t, 1H, J = Hz, H-1’), 4.67-4.64 (dd, 
1H), 4.54-4.49 (m, 1H), 4.23-4.20 (m, 1H), 3.30-3.26 (s, 3H, 5-CH3), 2.41-2.37 (m, 1H), 2.31-
2.25 (m, 1H), 1.67 (s, 3H, 5-CH3), 1.78-1.73 (m, 2H, H-2’,  H-2’’). 13C NMR (125MHz, 
MeOD): δ 168.5, 166.4, 153.3, 136.4, 135.5, 132.0, 131.5, 130.7, 111.6, 88.5, 87.0, 73.2, 66.3, 
49.9, 42.0, 29.0, 13.9. 
4.2.4 5’-O-benzoyl-N3-methyl-3’-O-trityl-thymidine (8). In a 25 ml round bottom flask, 
compound 7 (200 mg, 0.55 mmol) was evaporated 3 times with 5 mL of anhydrous pyridine 
and dissolved in 2 mL of anhydrous pyridine. Trityl chloride (340.4 mg, 1.22 mmol) was added 
under argon atmosphere. The mixture was stirred at 85 °C and reaction progress was monitored 
using TLC. After 18h, the mixture was cooled to room temperature, quenched with 1.5mL of 
MeOH and stirred for 30 min. The mixture was evaporated to dryness. The obtained crude 
compound was purified by column chromatography to obtain 220 mg (66%) of 8. TLC (ethyl 
acetate/hexane, 1:1): Rf = 0.90. 1H NMR (500MHz, MeOD): δ 7.49-7.11 (m, 20H), 7.09-7.08 
(d, 2H), 6.50-6.49 (t, 1H, H-1’), 4.43-4.41 (d, 1H), 4.29-4.24 (m, 1H) 4.06-4.05 (d, 1H), 3.81-
3.76 (m, 1H), 3.32 (s, 3H, N-CH3), 2.31-2.24 (m, 1H), 1.82-1.71 (m, 1H), 1.59 (s, 3H, 5-CH3); 
13C NMR (125MHz, CDCl3): δ 165.6, 163.1, 150.7, 143.6, 133.2, 132.2, 129.1, 128.5, 128.3, 
127.9, 127.3, 109.8, 87.8, 85.7, 83.5, 74.2, 63.9, 39.6, 27.5, 12.5. HRMS (EI+): m/z for 
[C37H35N2O6]+ calcd. 603.2489; found 603.2501. 
 
  
 
 
 
 
 
4.2.5. N3-methyl-3’-O-trityl-thymidine (9). An amount of 200 mg (0.33 mmol) of 8 was 
dissolved in 8.0 mL of absolute MeOH and was stirred at room temperature while LiOH (80 
mg, 1.90 mmol) in H2O (8 mL) was added to the reaction mixture. After 18 h TLC indicated 
product formation. The reaction mixture was extracted with CH2Cl2 (10 mL x 2). The organic 
layer was dried over MgSO4, filtered and the solvent was removed by rotary evaporation. The 
crude product was purified by column chromatography to obtain 110 mg (66%) of pure 9. TLC 
(CH2Cl2/MeOH, 9:1): Rf = 0.40. 1H NMR (500 MHz, CDCl3): δ 7.49-7.44 (m, 6H), 7.34-7.29 
(m, 6H), 7.28-7.24 (m, 3H), 7.19 (s, 1H),  6.14 (dd, 1H, J = 5.50 Hz, H-1’), 4.42-4.38 (m, 1H, 
H-3’), 3.95-3.91 (m, 1H, H-4’), 3.64-3.58 (m, 1H, H-5’/H-5’’), 3.26(s, 3H, N-CH3), 3.27-3.22 
(m, 1H, H-5’/H-5’’), 2.05-1.98 (m, 1H, H-2’/H-2’’ ), 1.89 (s, 3H, 5-CH3), 1.79-1.73 (m, 1H, 
H-2’/H-2’’). 13C NMR (125MHz, CDCl3): δ 163.5 (C-4), 151.1 (C-2), 144.2 , 135.1 (C-6), 
128.8 , 128.1 , 127.4 , 110.1 (C-5), 89.0 (C-1’), 87.8, 86.6 (C-4’), 74.6 (C-3’), 62.6 (C-5’), 38.5 
(C-2’), 27.8 (N-CH3), 13.2 (5-CH3). HRMS (EI+): m/z for [C30H30N2O5Na]+ calcd. 521.2052; 
found 521.2048. 
4.2.6. N3-methyl-3’,5’-di-O-trityl-thymidine (10).  In a 25 ml round bottom flask 100 mg (0.39 
mmol) of 5 was evaporated 3 times with 5 mL of anhydrous pyridine and dissolved in 3 mL of 
anhydrous pyridine. Trityl chloride (544 mg, 1.95 mmol) was added to the reaction mixture. 
The mixture was heated at 85 °C for 18 h under argon atmosphere. After 18h, the mixture was 
cooled to room temperature, quenched with 3 mL of MeOH and stirred for 30 min. The mixture 
was evaporated to dryness. The obtained crude compound was purified by column 
 
  
 
 
 
 
 
chromatography to obtain 220 mg (76%) of 10. TLC (ethyl acetate): Rf = 0.80. 1H NMR (500 
MHz, CDCl3): δ 7.50(s, 1H), 7.38-7.35 (m, 6H), 7.28-7.10 (m, 24H),  6.52-6.40 (dd, 1H, J = 
5.50 Hz, H-1’), 4.39-4.37 (m, 1H, H-3’), 3.81-3.80 (m, 1H, H-4’), 3.34 (s, 3H, N-CH3), 3.23-
3.19 (m, 1H, H-5’/H-5’’), 2.84-2.81 (m, 1H, H-5’/H-5’’), 2.03-1.98 (m, 1H, H-2’/H-2’’), 1.95-
1.90 (m, 1H, H-2’/H-2’’), 1.89 (s, 3H, 5-CH3). 13C NMR (125MHz, CDCl3): δ 163.7 (C-4), 
151.2 (C-2), 144.0 , 143.3, 133.6 (C-6), 128.7 , 128.5 , 128.0 , 127.9 , 127.3 , 127.2, 110.0 (C-
5), 87.8, 87.3, 85.8 (C-4’), 85.3 (C-1’), 75.4 (C-3’), 63.8 (C-5’), 39.9 (C-2’), 27.9 (N-CH3), 
12.5 (5-CH3). HRMS (EI+): m/z for [C49H45N2O5]+ calcd. 741.3323; found 741.3327. 
4.2.7. N3-methyl-3’,5’-di-O-methyl-thymidine (11).  To a suspension of sodium hydride (11.2 
mg, 0.46 mmol) in anhydrous DMF (0.5 mL) at 0 °C under argon was added dropwise 
compound  5 (50 mg, 0.20 mmol) dissolved in DMF (0.5 mL). The mixture was stirred for 20 
min at room temperature. Methyl iodide (29.2 µL, 0.46 mmol) was added to the solution at 
room temperature, and the reaction mixture was sonicated for 45 min. The solvent was removed 
in vacuo, and purification by flash chromatography (elution with 60-90% ethyl acetate in 
hexane) afforded compound 11 (30 mg, 52%) as a white foam. TLC (ethyl acetate): Rf = 
0.70. 1H NMR (500 MHz, CDCl3): δ 7.61(s, 1H), 6.35-6.32 (t, 1H, H-1’), 4.20-4.10 (m, 1H), 
4.10-4.00 (m, 1H), 3.70-3.66 (m, 1H), 3.59-3.56 (m, 1H), 3.44(s, 3H), 3.35(s, 3H), 3.34(s, 3H), 
2.44-2.40 (m, 1H, H-2’/H-2’’), 2.07-2.00 (m, 1H, H-2’/H-2’’), 1.94 (s, 3H, 5-CH3). 13C NMR 
(125MHz, CDCl3): δ 163.7, 133.8, 109.7, 85.9, 83.7, 81.1, 73.0, 59.1, 56.9, 37.5, 27.8, 13.5. 
HRMS (EI+): m/z for C13H20N2O5Na]+ calcd. 307.1264; found 307.1263. 
 
  
 
 
 
 
 
4.2.8. 5’-O-dodecyl-N3-methyl-thymidine (12).  To a suspension of sodium hydride (60% 
dispersion in oil , 10 mg, 0.45 mmol) in anhydrous DMF (0.5 mL) was added compound 5 (50 
mg, 0.39 mmol) in DMF (0.5 mL) at 0 °C under argon atmosphere. The mixture was stirred for 
20 min at 0 °C. The 1-bromododecane (103.2 µL, 0.43 mmol) was added to the solution and 
the reaction mixture was allowed to stir at room temperature for 2 h. The solvent was removed 
in vacuo, and purification by flash chromatography (elution with 5% methanol in CH2Cl2) 
afforded compound 12 (20 mg, 23%) as a colourless oil. TLC (CH2Cl2/MeOH, 9:1): Rf = 
0.80. 1H NMR (300 MHz, CDCl3): δ 7.62 (s, 1H), 6.46-6.42 (m, 1H, H-1’), 4.53-4.51 (m, 1H), 
4.11-4.09 (m, 1H), 3.76-3.71 (m, 1H), 3.65-3.60 (m, 1H), 3.56-3.46(m, 2H), 3.35 (m, 3H), 2.41-
2.33 (m, 1H, H-2’/H-2’’), 2.32(bs, 1H, OH), 2.24-2.15 (m, 1H, H-2’/H-2’’), 1.95 (s, 3H, 5-
CH3), 1.69-1.57 (m, 2H), 1.34-1.20 (m, 18H), 0.89-0.87 (m, 3H); 13C NMR (75MHz, CDCl3) 
δ: 163.7, 133.7, 109.8, 85.8, 85.7, 72.6, 71.9, 70.6, 41.1, 31.9, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 
27.8, 26.2, 22.7, 14.1, 13.4; HRMS (EI+): m/z for [C23H41N2O5]+ calcd. 425.3000; found 
425.2992. 
4.2.9. 3’,5’-di-O-dodecyl-N3-methyl-thymidine (13).  To a suspension of sodium hydride (23.4 
mg, 0.98 mmol) in anhydrous DMF (2 mL) at 0 °C under argon was added dropwise compound 
5 (100 mg, 0.41 mmol) dissolved in DMF (2 mL). The mixture was stirred for 15 min at room 
temperature. An amount of 1-bromododecane (281.3 µL, 1.17 mmol) was added to the solution 
at room temperature.  The reaction mixture was sonicated for 45 min and was allowed to stir at 
room temperature for 2 h. The solvent was removed in vacuo, and purification by flash 
 
  
 
 
 
 
 
chromatography (elution with 10-20% ethyl acetate in hexane) afforded 13 (155 mg, 68%) as a 
colourless oil. TLC (ethyl acetate/hexane 1:1): Rf = 0.80. 1H NMR (500 MHz, CDCl3): δ 7.63(s, 
1H), 6.36-6.34 (m, 1H, H-1’), 4.13-4.11 (m, 1H), 4.08-4.06 (m, 1H), 3.74-3.72 (m, 1H), 3.57-
3.53 (m, 2H), 3.48-3.43(m, 2H), 3.40-3.37(m, 1H), 3.34(s, 3H), 2.41-2.38 (m, 1H, H-2’/H-2’’), 
2.06-2.03 (m, 1H, H-2’/H-2’’), 1.94 (s, 3H, 5-CH3), 1.63-1.55 (m, 4H), 1.40-1.20 (m, 36H), 
0.89-0.87 (m, 6H). 13C NMR (125MHz, CDCl3): δ 163.7, 151.1, 133.7, 109.6, 85.9, 84.0, 79.5, 
71.8, 70.9, 69.6, 38.1, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 27.8, 26.2, 26.1, 22.7, 14.1, 13.4; 
HRMS (EI+): m/z for [C35H65N2O5]+, calcd. 593.4887; found 593.4883. 
4.2.10. 3’,5’-di-O-benzyl-N3-methyl-thymidine (14).  Compound 5 (100 mg, 0.41 mmol) in 
DMF (2 mL) was added dropwise to suspension of sodium hydride (23.4 mg, 0.98 mmol) in 
anhydrous DMF (2 mL) at 0 °C under argon atmosphere. The mixture was stirred for 15 min at 
room temperature. Benzyl bromide (140.0 µL, 1.17 mmol) was added to the solution at room 
temperature.  The reaction mixture was allowed to stir at room temperature for 2 h. The solvent 
was removed in vacuo, and purification by flash chromatography (elution with 40-70% ethyl 
acetate in hexane) afforded 153 mg, (86%) of 14 as a white solid. TLC (ethyl acetate/hexane 
2:1): Rf = 0.80. 1H NMR (500 MHz, CDCl3): δ 7.57 (s, 1H), 7.38-7.28 (m, 10H) 6.45-6.41 (m, 
1H, H-1’), 4.63-4.49 (m, 4H, 2CH2), 4.30-4.26 (m, 2H, H-3’ and H-4’), 3.86-3.81 (m, 1H, H-
5’), 3.68-3.64(m,  1H, H-5’’), 3.34 (s, 3H, N-CH3), 2.53-2.48 (m, 1H, H-2’/ H-2’’), 2.17-2.07 
(m, 1H, H-2’/ H-2’’), 1.69 (s, 3H, 5-CH3); 13C NMR (75MHz, CDCl3) δ: 163.6, 151.0, 137.5, 
 
  
 
 
 
 
 
137.4, 133.6, 128.5, 128.0, 127.9, 127.6, 127.4, 109.8, 85.8, 83.8, 78.9, 73.5, 71.4, 70.2, 38.0, 
27.7, 12.9; HRMS (EI+): m/z for [C25H29N2O5]+ calcd. 437.2071; found 437.2088. 
4.2.11. 5’-O-benzyl-N3-methyl-thymidine (15) and 3’-O-benzyl-N3-methyl-thymidine (16).  To 
a suspension of sodium hydride (60% dispersion in oil , 10 mg, 0.45 mmol) in anhydrous DMF 
(0.5 mL) was added dropwise compound 5 (50 mg, 0.39 mmol) in DMF (0.5 mL) at 0 °C under 
argon atmosphere. The mixture was stirred for 20 min. Benzyl bromide (51 µL, 0.43 mmol) 
was added to the solution at and was allowed to stir at 0 °C for 4 h. The solvent was removed 
in vacuo, and purification was done by flash chromatography (elution with 5% Methanol in 
CH2Cl2) affording 15 (18 mg, 26%) and 16 (16 mg, 23%) as a white foams.  
5’-O-benzyl-N3-methyl-thymidine (15): TLC (CH2Cl2/MeOH, 9:1): Rf = 0.60. 1H NMR 
(500MHz, MeOD): δ 7.56(s, 1H), 7.37-7.30 (m, 5H), 6.43 (t, 1H, J = 6.6 Hz, H-1’), 4.59 (s, 
2H), 4.55-4.54 (m, 1H, H-3’), 4.11-4.10 (m, 1H, H-4’), 3.82 -3.79 (m, 1H, H-5’), 3.72-3.70 (m, 
1H, H-5’’), 3.31 (s, 3H, N-CH3), 2.59 (bs, 1H, OH), 2.38-2.34 (m, 1H, H-2’), 2.24-2.19(m, 1H, 
H-2’’), 1.68 (s, 3H, 5-CH3). 13C NMR (125MHz, MeOD): δ 163.7 (C-4), 151.1 (C-2), 137.4, 
133.7 (C-6), 128.6, 128.0, 127.5, 110.0 (C-5), 85.8 (C-1’), 73.6 (C-4’), 72.4 (C-3’), 70.1, 62.9 
(C-5’), 41.0 (C-2’), 27.8 (N-CH3), 13.0 (5-CH3). HRMS (EI+):  m/z for [C18H23N2O5]+ calcd. 
347.1601; found 347.1608.  
3’-O-benzyl-N3-methyl-thymidine (16): TLC (CH2Cl2/MeOH, 9:1): Rf = 0.70. 1H NMR 
(500MHz, MeOD): δ 7.39-7.29 (m, 6H), 6.12 (t, 1H, J = 7.44 Hz, H-1’), 4.59-4.52 (m, 2H), 
4.32-4.30(m, 1H, H-3’), 4.18-4.16 (m, 1H, H-4’), 3.94-3.92 (m, 1H, H-5’), 3.77-3.75 (m, 1H, 
 
  
 
 
 
 
 
H-5’’), 3.33 (s, 3H, N-CH3), 2.71(bs, 1H, OH), 2.42-2.36 (m , 2H, H-2’,  H-2’’), 1.93 (s, 3H, 
5-CH3). 13C NMR (125MHz, MeOD): δ 163.5 (C-4), 151.0 (C-2), 137.4, 135.0 (C-6), 128.5, 
128.0, 127.7, 110.1 (C-5), 88.6 (C-1’), 85.2 (C-4’), 78.7 (C-3’), 71.6,  62.9 (C-5’), 37.1 (C-2’), 
27.8 (N-CH3), 13.3 (5-CH3). HRMS (ES+): m/z for [C18H23N2O5]+, calcd. 347.1601; found 
347.1609. 
4.2.12. 5’-O-trityl-thymidine (17) [27].  In a 25 ml round bottom flask 100 mg (0.39 mmol) of 
4 was evaporated 3 times with 3 mL of dry pyridine and dissolved in 3 mL of dry pyridine. 
Trityl chloride (120.0 mg, 0.43 mmol) was added and the reaction mixture was heated at 65 °C 
for 16 h under argon atmosphere. After 16 h, the mixture was cooled to room temperature, 
quenched with 3 mL of MeOH and stirred for 30 min. The mixture was evaporated to dryness. 
The obtained crude compound was purified by column chromatography to obtain 92 mg (48%) 
of 17. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.70. 1H NMR (500 MHz, CDCl3): δ 8.61(bs, 1H), 7.56 
(s, 1H), 7.42-7.26 (m, 15H),  6.42-6.40 (m, 1H, H-1’), 4.58 (s, 1H), 4.20-4.10 (m, 1H), 3.49-
3.46 (m, 1H), 3.40-3.37 (m, 1H), 2.44-2.40 (m, 1H, H-2’/H-2’’), 2.34-2.30 (m, 1H, H-2’/H-
2’’), 1.48 (s, 3H, 5-CH3). 13C NMR (125MHz, CDCl3): δ 163.6, 150.3, 143.3, 135.5, 128.6, 
128.2, 128.0, 127.5, 111.3, 87.5, 86.0, 84.6, 72.4, 70.7, 63.7, 40.9, 11.9; HRMS (EI+): m/z for 
[C42H48N4O10Na]+, calcd. 507.1890; found 507.1907 
4.2.13. 5’-O-benzoyl-thymidine (18) [28].  Thymidine 4 (100 mg, 0.41 mmol) was evaporated 
3 times with 5 mL of anhydrous pyridine and then dissolved in 2mL of anhydrous pyridine. 
Reaction was cooled at 0 °C and benzoyl chloride (51 µL, 0.43 mmol) was added to the reaction 
 
  
 
 
 
 
 
mixture. The mixture was stirred for 2 h at 0 °C under argon atmosphere. Reaction progress 
was monitored using TLC. After completion the mixture was evaporated to dryness. The 
obtained crude compound was purified by column chromatography (CH2Cl2/MeOH, 95:5) to 
obtain 120 mg (84%) of 18. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.60. 1H NMR (300MHz, CDCl3): 
11.32 (s, 1H, OH), 8.01-7.98 (m, 2H), 7.71-7.66 (m, 1H), 7.55 (t, 2H, J = 7.65 Hz), 7.40 (2, 
1H), 6.22 (t, 1H, J = 6.9 Hz), 5.49 (d, 1H, J = 4.5 Hz), 4.58-4.39 (m, 3H), 4.08-4.05 (m, 1H), 
2.30-2.09 (m, 2H), 1.60 (s, 3H, 5-CH3);  13C NMR (75MHz, CDCl3): δ 165.7, 163.7, 150.5, 
135.8, 133.7, 129.5,129.3, 129.0, 109.9, 83.9, 83.8, 70.4, 64.5, 12.0. HRMS (EI+): m/z for 
[C17H18N2O6Na]+ calcd. 369.1057; found 369.1056. 
4.2.14. 5’-O-benzoyl-3’-O-trityl-thymidine (19).  In a 25 ml round bottom flask 108 mg (0.31 
mmol) of 18 was evaporated 3 times with 2 mL of anhydrous pyridine and dissolved in 0.5 mL 
of anhydrous pyridine. Trityl chloride (191.4 mg, 0.69 mmol) was added. The mixture was 
stirred at 85 °C under argon atmosphere and reaction progress was monitored using TLC. After 
18h, the mixture was cooled to room temperature, quenched with 1.5mL of MeOH and stirred 
for 30 min. The mixture was evaporated to dryness. The crude compound was purified by 
column chromatography to obtain 75 mg (40 %) of 19. TLC (CH2Cl2/MeOH, 9:1): Rf = 
0.80. 1H NMR (500MHz, MeOD): δ 7.88 (d, 1H), 7.65-6.27 (m, 20H), 4.49-4.47 (m, 1H), 4.32-
4.27 (m, 1H) 4.06-4.00 (m, 1H), 2.06-2.02 (m, 1H), 1.80-1.56 (m, 1H), 1.55 (s, 3H, 5-CH3); 13C 
NMR (75MHz, CDCl3): δ 165.6, 163.0, 149.8, 143.6, 134.4, 133.2, 129.1, 128.5, 128.3, 127.9, 
 
  
 
 
 
 
 
127.3, 110.8, 87.8, 85.0, 83.5, 74.2, 64.0, 39.5, 11.7. HRMS (EI-): m/z for [C36H31N2O6]- 
calcd. 587.2187; found 587.2181. 
4.2.15. 3’-O-trityl-thymidine (20) [29].  The product 19 (50 mg, 0.09 mmol) was dissolved in 1 
mL of absolute MeOH and was stirred at rt. LiOH (17.9 mg, 0.43 mmol) in H2O (2 mL) was 
added to the reaction mixture. After 5 h TLC indicates product formation. The reaction mixture 
was extracted with CH2Cl2 (10 mL x 2). The organic layer was washed with water (5 mL x 1), 
dried over MgSO4, filtered and the solvent was removed by rotary evaporation. The crude 
product was purified by column chromatography to obtain 25 mg (61%) of pure 20. TLC (ethyl 
acetate/hexane, 1:1): Rf = 0.20. 1H NMR (500 MHz, CDCl3): δ 7.68 (s, 1H), 7.51-7.46 (m, 6H), 
7.37-7.31 (m, 6H), 7.30-7.25 (m, 3H),  6.31 (t, 1H, J = 5.50 Hz, H-1’), 4.42-4.35 (m, 1H, H-
3’), 3.85-3.78 (m, 1H, H-4’), 3.48-3.42 (m, 1H, H-5’/H-5’’), 3.27-3.22 (m, 1H, H-5’/H-5’’), 
1.81 (s, 3H, 5-CH3), 1.77-1.75 (m, 2H, H-2’,  H-2’’). 13C NMR (125MHz, MeOD): δ 166.4 (C-
4), 152.5 (C-2), 145.8, 138.0 (C-6), 130.1, 129.1, 128.5, 111.7 (C-5), 89.2, 88.1 (C-4’), 86.4 
(C-1’), 76.5 (C-3’), 63.0 (C-5’), 40.4 (C-2’), 12.4(5-CH3); HRMS (EI+): m/z for 
[C29H28N2O5Na]+ calcd. 507.1890; found 507.1884. 
4.2.16. 3’,5’-di-O-trityl-thymidine (21) [29].  In a 25 ml round bottom flask 100 mg (0.41 mmol) 
of 4 was co-evaporated 3 times with 2 mL of dry pyridine and dissolved in 2 mL of dry pyridine. 
Trityl chloride (287.5 mg, 1.03 mmol) was added under argon atmosphere. The mixture was 
heated at 65 °C for 16 h. After 16 h, the mixture was cooled to room temperature, quenched 
with 3 mL of MeOH and stirred for 20 min. The mixture was evaporated to dryness. The 
 
  
 
 
 
 
 
obtained crude compound was purified by column chromatography to obtain 251 mg (84%) of 
21 as white foam. TLC (ethyl acetate/hexane, 1:1): Rf = 0.60. 1H NMR (500 MHz, CDCl3): δ 
8.61(bs, 1H), 7.56 (s, 1H), 7.42-7.26 (m, 15H),  6.42-6.40 (m, 1H, H-1’), 4.58 (s, 1H), 4.20-
4.10 (m, 1H), 3.49-3.46 (m, 1H), 3.40-3.37 (m, 1H), 2.44-2.40 (m, 1H, H-2’/H-2’’), 2.34-2.30 
(m, 1H, H-2’/H-2’’), 1.48 (s, 3H, 5-CH3). 13C NMR (125MHz, CDCl3): δ 163.6, 150.3, 143.3, 
135.5, 128.6, 128.2, 128.0, 127.5, 111.3, 87.5, 86.0, 84.6, 72.4, 70.7, 63.7, 40.9, 11.9; HRMS 
(EI+): m/z for [C48H42N2O5Na]+ calcd. 749.2986; found 749.2991. 
4.2.17. 3’-O-benzyl-5’-O-trityl-thymidine (22).  To a suspension of 18.2 mg of sodium hydride 
(0.45 mmol) in anhydrous THF (1 mL) was added dropwise compound 17 (200 mg, 0.41 mmol) 
in THF (1 mL) at room temperature under argon atmosphere. The mixture was stirred at 50 °C 
for 1 h. An amount of benzyl bromide (54 µL, 0.45 mmol) was added to the solution and stirring 
was continued for 3 h. Reaction was monitored by TLC in 100% ethyl acetate. The solvent was 
removed in vacuo, and purification was done by flash chromatography (elution with 80-90% 
ethyl acetate in hexane) afforded 190 mg (80%) of 22. TLC (ethyl acetate): Rf = 0.70. 1H NMR 
(500MHz, MeOD): δ 7.52-7.48(m, 3H), 7.41-7.39 (m, 5H), 7.32-7.24 (m, 15H), 6.43-6.40 (m, 
1H, H-1’), 5.56-5.54 (m, 1H), 4.02-4.00 (m, 1H), 3.48-3.45 (m, 1H), 3.39-3.36 (m, 1H), 2.41-
2.37 (m, 1H), 2.32-2.26 (m, 1H), 1.53 (s, 3H, 5-CH3). 13C NMR (125MHz, MeOD): δ 163.4, 
151.0, 143.3, 136.9, 133.6, 129.3, 128.6, 128.4, 128.0, 127.4, 110.5, 87.5, 85.7, 85.3, 72.3, 63.6, 
44.5, 41.0, 12.7; HRMS (EI+): m/z for [C36H34N2O5Na]+ calcd. 597.2360; found 597.2361. 
 
  
 
 
 
 
 
4.2.18. 3’-O-benzyl-thymidine (23) [30].  The compound 22 (150 mg, 0.26mmol) was dissolved 
in 80% aqueous acetic acid (10 mL) and heated at 50 °C for 1 h. Solvent was removed in vacuo, 
and the crude product thus obtained was purified on silica gel column using MeOH/CH2Cl2 
(8:92, v/v) as eluent to give compound 23 (76 mg, 88%) as a solid. TLC (MeOH/CH2Cl2, 1:9): 
Rf = 0.50. 1H NMR (300MHz, CDCl3): δ 7.87(s, 1H), 7.35-7.23 (m, 5H), 6.33-6.30 (m, 1H, H-
1’), 5.10 (s, 2H), 4.41-4.38 (m, 1H), 3.92-3.90 (m, 1H), 3.82-3.79 (m, 1H), 3.74-3.71 (m, 1H), 
2.30-2.25 (m, 1H), 2.23-2.18 (m, 1H), 1.92 (s, 3H, 5-CH3); 13C NMR (75MHz, CDCl3) δ: 
162.9, 150.7, 136.5, 134.5, 128.9, 128.0, 127.3, 87.3, 86.4, 71.3, 62.1, 44.2, 39.8, 13.00; HRMS 
(EI+): m/z for [C17H21N2O5]+ calcd. 333.1444; found 333.1436. 
4.2.19. 3’,5’-di-O-benzyl-thymidine (24) [31]. To a suspension of sodium hydride (7.2 mg, 0.18 
mmol) in anhydrous THF (0.5 mL) was added 23 (50 mg, 0.15 mmol) in THF (0.5 mL) 
dropwise at room temperature under argon atmosphere. The mixture was stirred at 50 °C for 1 
h. An amount of benzyl bromide (21 µL, 0.18 mmol) was added to the solution and stirring was 
continued for 5 h. Reaction was monitored by TLC. The solvent was removed in vacuo, and 
purification was done by flash chromatography (elution with 30-50% ethyl acetate/hexane) 
afforded 34 mg (53%) of 24. TLC (ethyl acetate/hexane, 1:1): Rf = 0.60. 1H NMR (500MHz, 
MeOD): δ 7.67(s, 1H), 7.35-7.27 (m, 10H), 6.31-6.28 (m, 1H, H-1’), 4.61-4.53 (m, 4H),  4.32-
4.30 (m, 1H), 4.24-4.22 (m, 1H), 3.81-3.78 (m, 1H), 3.68-3.66 (m, 1H), 2.45-2.40 (m, 1H), 
2.23-2.17 (m, 1H), 1.55 (s, 3H, 5-CH3). 13C NMR (125MHz, MeOD): δ 166.3, 152.3, 139.5, 
 
  
 
 
 
 
 
137.8, 129.6, 129.5, 129.0, 128.8, 111.6, 86.5, 85.4, 80.6, 74.5, 72.2, 71.7, 31.7, 12.3; HRMS 
(EI+): m/z for [C24H26N2O5Na]+ calcd. 445.1734; found 445.1736. 
4.2.20. 5’-O-Fmoc-thymidine (25) [32].  Thymidine (4, 50 mg, 0.21 mmol) was dissolved and 
co-evaporated 3 times with 2 mL of dry pyridine and dissolved in 0.5 mL of dry pyridine. Fmoc 
chloride (64 mg, 0.25 mmol) was added to the reaction mixture. The mixture was allowed to 
stir at room temperature for 18 h under argon atmosphere. After 18h, mixture was evaporated 
to dryness. The obtained crude compound was purified by column chromatography to obtain 
50 mg (52%) of 25. TLC (CH2Cl2/MeOH, 9:1): Rf = 0.70. 1H NMR (500 MHz, CDCl3): δ 7.89 
(s, 1H), 7.79-7.76 (m, 2H), 7.60-7.58 (m, 2H), 7.43-7.40(m, 1H), 7.40-7.35 (m, 2H), 7.30-7.26 
(m, 2H),  6.30-6.22 (m, 1H, H-1’), 4.65-4.62 (m, 1H, H-3’), 4.50-3.47 (m, 1H), 4.44-4.41 (m, 
1H), 4.31-4.23 (m, 3H), 4.07-4.04 (m,1H), 2.25-2.20 (m, 1H, H-2’/H-2’’), 2.03-1.97 (m, 1H, 
H-2’/H-2’’), 1.67 (s, 3H, 5-CH3). 13C NMR (125MHz, CDCl3): δ 166.3, 156.4, 152.2, 144.7, 
144.6, 142.7, 142.6, 137.4, 129.0, 128.9, 128.2, 128.1, 126.0, 125.9, 121.1, 111.7, 86.4, 86.0, 
72.2, 70.7, 68.4, 40.9, 12.6; HRMS (EI+): m/z for [C25H24N2O7Na]+ calcd. 487.1475; found 
487.1470. 
4.2.21. 3’,5’-bis-O-Fmoc-thymidine (26). Thymidine 4 (50 mg, 0.21 mmol) was dissolved and 
co-evaporated 3 times with 2 mL of dry pyridine and dissolved in 1 mL of dry pyridine. Fmoc 
chloride (128 mg, 0.50 mmol) was added to the reaction mixture. The mixture was allowed to 
stir at room temperature for 18 h under argon atmosphere. After 18h, mixture was evaporated 
to dryness. The obtained crude compound was purified by column chromatography to obtain 
 
  
 
 
 
 
 
88 mg (62%) of 26. TLC (ethyl acetate): Rf = 0.90. 1H NMR (500 MHz, CDCl3): δ 8.40(bs, 
1H, NH), 7.80-7.74 (m, 4H), 7.63-7.54 (m, 4H), 7.45-7.38(m, 4H), 7.37-7.27 (m, 5H),  6.41-
6.38 (m, 1H, H-1’), 5.15-5.13(m, 1H), 4.63-4.59 (m, 1H, H-3’), 4.51-4.44 (m, 4H), 4.42-4.39 
(m, 1H), 4.30-4.24 (m, 3H), 2.54-2.50 (m, 1H, H-2’/H-2’’), 2.16-2.10 (m, 1H, H-2’/H-2’’), 1.78 
(s, 3H, 5-CH3). 13C NMR (125MHz, CDCl3): δ 163.2, 154.6, 154.4, 150.1, 143.0, 142.9, 141.4, 
134.7, 128.1, 128.0, 127.2, 127.1, 125.1, 124.9, 124.8, 120.2, 111.7, 84.7, 82.0, 77.8, 70.3, 70.1, 
67.2, 46.8, 46.7, 37.3, 12.6; HRMS (EI+): m/z for [C40H35N2O9]+ calcd. 687.2336; found 
687.2335. 
4.2.22. 5’-O-adamantyl-thymidine (27) and 3’,5’-bis-O-adamantyl-thymidine (28).  Thymidine 
4 (300 mg, 1.24 mmol) was co-evaporated 3 times with 5 mL of dry pyridine and dissolved in 
2mL of dry pyridine under argon atmosphere. A solution of adamantyl chloride in CH2Cl2 (2.3 
mL, 2.27 mmol) was added dropwise to the reaction mixture. The mixture was stirred at 70 °C 
and reaction progress was monitored using TLC. After 18 h, the mixture was cooled to room 
temperature. The mixture was evaporated to dryness. The obtained crude compound was 
purified by column chromatography (CH2Cl2/MeOH, 95:5) to obtain the title compounds 28 
(180 mg, 26%) and 27 (75 mg, 15 %). TLC (ethyl acetate/hexane, 1:1): Rf = 0.70 and 0.60. 
5’-O-adamantyl-thymidine (27)  1H NMR (500MHz, MeOD): δ 8.79 (bs, 1H), 7.26 (s, 1H), 
6.31-6.28 (m, 1H), 4.45-4.42 (m, 1H), 4.37-4.35 (m, 1H),  4.30-4.27 (m, 1H),  4.25-4.22 (m, 
1H), 4.18-4.16 (m,1H), 2.71 (bs, 1H), 2.49-2.44 (m, 1H), 2.12-2.07 (m, 1H), 2.04 (bs, H), 1.94 
(s, 3H, 5-CH3), 1.91-1.88 (m, 6H), 1.77-1.71 (m, 9H); 13C NMR (75MHz, CDCl3): δ 177.6, 
 
  
 
 
 
 
 
163.5, 150.2, 134.9, 101.2, 84.9, 85.0, 71.5, 63.5, 41.0, 40.6, 39.0, 36.3, 27.8, 12.5; HRMS 
(EI+): m/z for [C21H28N2O6Na]+ calcd. 427.1840; found 427.1835. 
3’,5’-bis-O-adamantyl-thymidine (28)  1H NMR (500MHz, MeOD): δ 7.30 (s, 1H), 6.30-6.27 
(m, 1H), 5.19-5.17 (m, 1H), 4.46-4.42 (m, 1H), 4.30-4.27 (m, 1H),  4.20-4.18 (m, 1H), 2.50-
2.46 (m, 1H), 2.13-2.04 (m, 1H), 2.03 (bs, 6H), 1.94 (s, 3H, 5-CH3), 1.90-1.84 (m, 12H), 1.77-
1.67 (m, 12H); 13C NMR (75MHz, CDCl3): δ 177.2, 177.0, 150.0, 134.5, 111.4, 84.8, 82.8, 
73.8, 63.7, 40.6, 39.1, 38.6, 37.9, 36.3, 29.7, 27.8, 12.5; HRMS (EI+): m/z for 
[C32H42N2O7Na]+ calcd. 589.2884; found 589.2886. 
4.2.23. 3’,5-di-O-acetyl-thymidine (29) [33]. A suspension of compound 4 (300 mg, 1.24 mmol) 
in acetonitrile (5 mL)was treated with triethylamine (0.692 mL, 4.95 mmol) and acetyl chloride 
(0.213 mL, 2.85 mmol) in the presence of a catalytic amount of 4-(dimethylamino)pyridine 
(DMAP) (15 mg, 0.12 mmol). The resulting mixture was stirred at room temperature for 5 h 
and was then diluted with CH2Cl2 and water (1:1). The organic phase was separated, washed 
with water (3 x 50 mL) and dried over Na2SO4, filtered and concentrated in vacuo. The residue 
was purified by silica gel column chromatography to afford 380 mg (94%) of 29. TLC (ethyl 
acetate/hexane, 1:1): Rf = 0.70.  1H NMR (300 MHz, CDCl3): δ 8.81(bs, 1H), 7.27(s, 1H), 6.35-
6.30 (m, 1H, H-1’), 5.23-5.21 (m, 1H), 4.41-4.24 (m, 3H), 2.50-2.35 (m, 1H), 2.27-2.24 (m, 
1H), 2.13 (s, 3H), 2.12 (s, 3H), 1.68 (s, 3H, 5-CH3); 13C NMR (75MHz, CDCl3): δ  170.4, 
170.2, 163.5, 150.3, 134.5, 111.6, 84.8, 82.1, 74.1, 63.8, 37.5, 20.9, 20.8, 12.7; HRMS (EI+): 
m/z for [C14H18N2O7K]+ calcd. 365.0751; found 365.0748. 
 
  
 
 
 
 
 
4.2.24. 3’,5’-di-O-(tert-butyldimethylsilyl)-thymidine (30) [34]. Thymidine 4 (200 mg, 0.826 
mmol) was dissolved in dry DMF (4 mL). Tert-butyldimethylsilyl chloride (871 mg, 5.78 
mmol) and imidazole (562 mg, 8.26 mmol) were added to the reaction mixture. The clear 
solution was allowed to stir at room temperature for 18 h. Water (40 mL) was added, the 
aqueous layer was extracted with ethyl acetate (3 x 50 mL), and the combined organic layers 
were washed with brine (3 x 50 mL), dried over Na2SO4, and concentrated to dryness. The oily 
residue was purified by silica gel column chromatography to give pure compound 30 (360 g, 
92%) as a white foam. TLC (ethyl acetate/hexane, 1:1): Rf = 0.70. 1H NMR (500MHz, CDCl3): 
δ 8.81 (bs, 1H), 7.45 (s, 1H), 6.35-6.33 (m, 1H, H-1’), 4.42-4.40 (m, 1H), 3.94-3.93 (m, 1H), 
3.89-3.86 (m, 1H), 3.78-375 (m, 1H), 2.27-2.24 (m, 1H), 2.03-1.98 (m, 1H), 1.91 (s, 3H, 5-
CH3); 13C NMR (125MHz, MeOD): δ 163.8, 150.3, 135.5, 110.8, 87.8, 84.8, 72.2, 63.0, 41.4, 
29.7, 25.9, 25.7, 12.5, -4.7, -4.9, -5.4, -5.5; HRMS (EI+): m/z for [C22H42N2O5Si2K]+ calcd. 
509.2269; found 509.2263. 
4.2.25. 3’,5’-di-O-(triisopropylsilyl)-thymidine (31) [35]. Thymidine 4 (200 mg, 0.826 mmol) 
was dissolved in dry DMF (4 mL). Triisopropylsilyl chloride (1.24 mL, 5.78 mmol) and 
imidazole (562 mg, 8.26 mmol) were added to the reaction mixture at room temperature. The 
obtained clear solution was allowed to stir at room temperature for 18 h. Water (40 mL) was 
added and the aqueous layer was extracted with ethyl acetate (3 X 50 mL). The combined 
organic layers were washed with brine (3 X 50 mL), dried over Na2SO4, and concentrated to 
dryness. The oily residue was purified by silica gel column chromatography to get 430 mg 
 
  
 
 
 
 
 
(94%) of pure compound 31 as white foam. TLC (ethyl acetate/hexane, 1:1): Rf = 0.70.1H NMR 
(500MHz, CDCl3): δ 8.46 (bs, 1H), 7.46 (s, 1H), 6.38-6.35 (m, 1H, H-1’), 4.63-4.61 (m, 1H), 
4.03-4.02 (m, 1H), 3.97-3.94 (m, 1H), 3.90-3.88 (m, 1H), 2.33-2.39 (m, 1H), 2.06-2.02 (m, 1H), 
1.91 (s, 3H, 5-CH3), 1.17-1.13 (m, 3H), 1.10-1.05 (m, 45H); 13C NMR (75MHz, CDCl3): δ 
163.6, 150.1, 135.4, 110.7, 88.4, 84.8, 72.7, 63.6, 41.8, 18.0, 17.9, 17.9, 17.7, 12.3, 12.3, 12.0, 
11.8; HRMS (EI+): m/z for [C28H55N2O5Si2]+ calcd. 555.3644; found 555.3656. 
4.2.26. 3’,5’-di-O-(tert-butyldiphenylsilyl)-thymidine (32).  Tert-butyldiphenylsilyl chloride 
(1.5 mL, 5.78 mmol) and imidazole (562 mg, 8.26 mmol) was added to a solution of 200 mg 
(0.826 mmol) of 4 in dry DMF (4 mL). The clear solution was stirred at room temperature for 
18 h. Reaction was quenched by adding 40 mL of water. The aqueous layer was extracted with 
ethyl acetate (3 X 50 mL). The combined organic layers were washed with brine (3 X 50 mL), 
dried over Na2SO4, and concentrated to dryness. The oily residue was purified by silica gel 
column chromatography to obtain compound 510 mg (87%) of 32 as white foam. TLC (ethyl 
acetate/hexane, 1:1): Rf = 0.60. 1H NMR (500MHz, CDCl3): δ 8.02 (bs, 1H), 7.65-7.63 (m, 
2H), 7.59-7.58 (m, 2H), 7.53-7.53 (m, 2H), 7.48-7.45 (m, 3H), 7.42-7.40 (m, 6H), 7.34-7.28 
(m, 6H), 6.53-6.51 (m, 1H, H-1’), 4.56-4.55 (d, 1H), 4.00-3.99 (m, 1H), 3.76-3.74 (m, 1H), 
3.31-3.29 (m, 1H), 2.35-2.32 (m, 1H), 2.00-1.96 (m, 1H), 1.49 (s, 3H, 5-CH3), 1.09 (s, 9H), 
0.94 (s, 9H); 13C NMR (75MHz, CDCl3): δ 163.3, 150.1, 135.7, 135.7, 135.4, 135.4, 135.1, 
133.2, 133.1, 133.0, 132.1, 130.0, 130.0, 130.0, 127.9, 127.9, 111.0, 87.8, 84.4, 74.0, 64.0, 41.3, 
 
  
 
 
 
 
 
26.9, 19.3, 19.0, 11.9; HRMS (EI+): m/z for [C42H51N2O5Si2]+ calcd. 719.3330; found 
719.3328. 
4.2.27. 3’,5’-di-O-(tert-butylphenylmethoxysilyl)-thymidine (33).  To a solution of 4 (200 mg, 
0.826 mmol) in dry DMF (4 mL), tert-butylphenylmethoxysilyl bromide (0.46 mL, 2.06 mmol) 
and imidazole (281 mg, 4.13 mmol) were added to obtain a clear solution. The reaction mixture 
was allowed to stir at room temperature for 18 h. Water (40 mL) was added to the reaction 
mixture. The aqueous layer was extracted with ethyl acetate (3 X 50 mL), and the combined 
organic layers were washed with brine (3 X 50 mL), dried over Na2SO4, and concentrated to 
dryness. The oily residue was purified by silica gel column chromatography to give pure 
compound 33 (450 mg, 87%) as a white foam. TLC (ethyl acetate/hexane, 1:1): Rf = 0.60. 1H 
NMR (500MHz, CDCl3): δ 8.58 (bs, 1H), 7.65-7.33 (m, 10H), 6.52-6.45 (m, 1H, H-1’), 4.86-
4.76 (m, 1H), 4.18-4.15 (m, 1H), 4.13-3.87 (m, 2H), 3.70-3.50 (m, 6H), 2.50-2.44 (m, 1H), 
2.17-2.06 (m, 1H), 1.26 (s, 3H), 1.00-0.97 (m, 9H), 0.92-0.90 (m, 9H); 13C NMR (75MHz, 
CDCl3): δ 163.1, 150.2, 135.2, 134.9, 131.2, 130.4, 130.3, 130.2, 128.0, 127.9, 111.1, 87.7, 
87.6, 84.8, 84.4, 72.7, 72.4, 63.7, 63.0, 51.8, 51.7, 51.4, 41.5, 41.4, 41.3, 29.7, 26.1, 26.1, 18.7, 
18.7, 12.3, 12.2, 11.7; HRMS (EI+): m/z for [C32H46N2O7Si2Na]+ calcd. 649.2735; found 
649.2711. 
4.2.28. 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methyl-4-(1H-
1,2,4-triazol-1-yl)pyrimidin-2(1H)-one (34).[14]Triethylamine (10.5 mL, 75.3 mmol) and 
chlorotrimethylsilane (3.2 mL, 25.2 mmol) were added to a stirred suspension of thymidine 4 
 
  
 
 
 
 
 
(1.22 g, 5.04 mmol) in acetonitrile (40 mL) at room temperature. After 1.5 h, the reaction 
mixture was cooled (ice water bath), and 1,2,4-1H-triazole (3.12 g, 45.2 mmol) and phosphorus 
oxychloride (0.95 mL, 10.2 mmol) were added with continued stirring. After a period of 5 h, 
the product was poured into saturated aqueous sodium hydrogen carbonate (250 mL), and the 
resulting mixture was extracted with dichloromethane (2 x 25 mL). The combined organic 
extracts were dried (Na2SO4) and evaporated under reduced pressure. Acetic acid- methanol 
(1:4 v/v, 15 mL) was added to the residue, and the resulting solution was allowed to stir at room 
temperature. After 4.5 h, diethyl ether (30 mL) was added drop wise, with stirring, to this 
solution over a period of 30 min. After a further period of 2 h, colourless crystals of the target 
compound 34 (1.30 g, 88%) were collected by filtration. 1H NMR (300 MHz, DMSO): δ 9.23(s, 
1H), 8.62 (s, 1H), 8.38 (s, 1H), 6.13 (t, 1H, J = 6 Hz), 5.31 (bs, 1H), 5.22 (bs, 1H), 4.28-4.25 
(m, 1H), 3.92-3.60 (m, 3H), 3.12- 3.05 (m, 1H), 2.42-2.11 (m, 5H); 13C NMR (75MHz, CDCl3) 
δ: 157.9, 153.5, 153.2, 148.0, 145.4, 104.5, 88.2, 87.0, 69.4, 60.5, 45.7, 41.1, 16.3, 8.7; HRMS 
(EI+): m/z for [C12H16N5O4]+ calcd. 294.1197; found 294.1201. 
4.2.29. O4-methyl thymidine (35) [14]. In a 25 ml round bottom flask the triazolide 34 (590 mg, 
2.0 mmol) was dissolved in anhydrous methanol. Sodium methoxide in methanol (0.5 ml, 30% 
w) was added to the reaction mixture which was stirred at room temperature. After 15 min, the 
reaction mixture was evaporated under reduced pressure and the residue was redissolved in 
methanol (0.5 mL). The suspension was purified by column chromatography (methanol/ DCM, 
1:9) to get a white solid 35 (300 mg, 60 %). 1H NMR (300 MHz, CD3OD): δ 8.28 (bs, 1H), 
 
  
 
 
 
 
 
8.02 (s, 1H), 6.15 (t, 1H, J = 6.6 Hz), 4.26-4.21 (m, 1H), 3.85 (s, 3H, CH3), 3.83-3.80 (m, 1H), 
3.67-3.64 (m, 2H), 2.24-2.16 (m, 1H), 2.02-1.96 (m, 1H), 1.99 (s, 3H, CH3); 13C NMR (75MHz, 
CD3OD) δ: 170.1, 154.8, 141.0, 103.0, 87.7, 85.6, 70.1, 61.1, 54.2, 40.7, 12.0; HRMS (EI+): 
m/z for [C11H16N2O5Na]+ calcd. 279.0952; found 279.0948. 
4.2.30. 5-fluoro-5’-O-trityl-2’-deoxyuridine (38) [36]. In a 25 ml round bottom flask an amount 
of 100 mg (0.41 mmol) of 37 was co-evaporated 3 times with 5 mL of dry pyridine and 
dissolved in 3 mL of dry pyridine. Trityl chloride (136 mg, 0.49 mmol) was added to the 
reaction mixture. The mixture was heated at 50 °C for 18 h. After 18h, the mixture was cooled 
to room temperature, quenched with 3 mL of MeOH and stirred for 30 min. The mixture was 
evaporated to dryness. The obtained crude compound was purified by column chromatography 
to obtain 140 mg (70 %) of 38. TLC (MeOH/ CH2Cl2, 1:9): Rf = 0.80. 1H NMR (300 MHz, 
CDCl3): δ 8.70 (s, 1H), 7.82 (d, 1H), 7.46-7.43 (m, 6H), 7.37-7.28 (m, 11H),  6.32-6.28 (m, 
1H, H-1’), 4.57-4.55 (m, 1H), 4.08-4.06 (m, 1H), 3.48-3.46 (m, 2H, H-5’/H-5’’), 2.54-2.46 (m, 
1H, H-2’/H-2’’), 2.32-2.19 (m, 1H, H-2’/H-2’’); 13C NMR (75MHz, CDCl3): δ 149.5, 148.5, 
138.9, 128.5, 128.1, 127.5, 124.2, 123.8, 87.8, 86.1, 85.4, 71.7, 63.2, 41.1; HRMS (EI+): m/z 
for [C28H25FN2O5Na]+ calcd. 511.1639; found 511.1638. 
4.2.31. 5-fluoro-3’,5’-di-O-trityl-2’-deoxyuridine (39).  In a 25 ml round bottom flask an 
amount of 100 mg (0.41 mmol) of 37 was evaporated 3 times with 5 mL of dry pyridine and 
dissolved in 3 mL of dry pyridine. Tritylchloride (340 mg, 1.22 mmol) was added to the reaction 
mixture. The mixture was heated at 85 °C for 18 h under argon atmosphere. After 18h, the 
 
  
 
 
 
 
 
mixture was cooled to room temperature, quenched with 3 mL of MeOH and stirred for 30 min. 
The mixture was evaporated to dryness. The obtained crude compound was purified by column 
chromatography to obtain 200 mg (67 %) 39. TLC (ethyl acetate/hexane 1:1): Rf  = 0.80. 1H 
NMR (300 MHz, CDCl3): δ 8.10 (bs, 1H), 7.73 (d, 1H), 7.43-7.40 (m, 6H), 7.29-7.25 (m, 25H),  
6.37-6.33 (m, 1H, H-1’), 3.89 (s, 1H), 3.19-3.15 (m, 1H, H-5’/H-5’’), 3.04-3.00 (m, 1H, H-
5’/H-5’’), 2.07-1.97 (m, 1H, H-2’/H-2’’), 1.90-1.84 (m, 1H, H-2’/H-2’’); 13C NMR (75MHz, 
CDCl3) δ: 148.2, 143.6, 142.8, 141.6, 138.5, 128.4, 127.8, 127.7, 127.1, 127.0, 124.1, 123.7, 
87.6, 87.3, 85.5, 85.3, 74.9, 63.4; HRMS (EI+): m/z for [C47H39FN2O5Na]+ calcd. 753.2735; 
found 753.2725. 
4.2.32. 5-fluoro-5’-O-trityl-uridine (41) [37]. An amount of 100 mg (0.38 mmol) of 40 was co-
evaporated 3 times with 5 mL of dry pyridine and dissolved in 3 mL of dry pyridine in a 25 ml 
round bottom. Tritylchloride (128 mg, 0.46 mmol) was added to the reaction mixture. The 
mixture was heated at 50 °C for 18 h under argon atmosphere. After 18h, the mixture was 
cooled to room temperature, quenched with 3 mL of MeOH and was allowed to stir for 30 min. 
The mixture was evaporated to dryness. The obtained crude compound was purified by column 
chromatography to obtain 122 mg (63 %) of 41. TLC (MeOH/ CH2Cl2, 1:9): Rf = 0.80. 1H 
NMR (300 MHz, CDCl3): δ 7.86 (d, 1H), 7.40-7.37 (m, 6H), 7.31-7.22 (m, 11H),  5.79-5.77 
(m, 1H, H-1’), 4.33-4.31 (m, 1H), 4.24-4.21 (m, 1H), 4.14-4.12 (m, 1H), 3.45-2.42 (m, 2H, H-
5’/H-5’’); 13C NMR (75MHz, CDCl3) δ: 149.4, 143.0, 142.0, 138.8, 128.4, 127.8, 127.2, 124.2, 
 
  
 
 
 
 
 
123.7, 89.5, 87.5, 83.6, 74.9, 69.8, 62.6; HRMS (EI+): m/z for [C28H25FN2O6Na]+ calcd. 
527.1589; found 527.1585. 
4.2.33. 5-fluoro-3’,5’-di-O-trityl-uridine (42) and 5-fluoro-2’,5’-di-O-trityl-uridine (43).  In a 
25 ml round bottom flask an amount of 100 mg (0.38 mmol) of 40 was co-evaporated 3 times 
with 5 mL of dry pyridine and then dissolved in 4 mL of dry pyridine. Tritylchloride (319 mg, 
1.14 mmol) was added to the reaction mixture. The mixture was heated at 80 °C for 18 h under 
argon atmosphere. After 18h, the mixture was cooled to room temperature, quenched with 4 
mL of MeOH and stirred for 30 min. The mixture was evaporated to dryness. The obtained 
crude compound was purified by column chromatography to obtain 10 mg of 42 and 10 mg of 
43.  
5-fluoro-3’,5’-di-O-trityl-uridine (42) [38]: TLC (ethyl acetate/hexane 1:1): Rf = 0.70. 1H NMR 
(500 MHz, CDCl3): δ 9.07 (bs, 1H), 7.79 (d, 1H), 7.37-7.35 (m, 6H), 7.27-7.21 (m, 25H),  6.10 
(d, 1H, H-1’), 4.30-4.28 (m, 1H, H-3’), 4.08-4.05 (m, 1H, H-2’), 3.41 (s, 1H, H-4’), 3.21-3.18 
(m, 1H, H-5’/H-5’’ and OH), 2.84-2.82 (m, 1H, H-5’/H-5’’). 13C NMR (125MHz, CDCl3): δ 
156.7 (CO), 156.6 (CO), 149.3, 143.4, 143.0, 128.7, 128.5, 128.2, 128.0, 127.7, 127.4, 89.3 
(C1’), 88.3 (quat. C), 88.1 (quat. C), 83.3 (C4’), 75.1 (C2’), 73.6 (C3’), 63.3 (C5’). HRMS 
(EI+): m/z for [C47H39FN2O6Na]+ calcd. 769.2684; found 769.2677. 
5-fluoro-2’,5’-di-O-trityl-uridine (43) [38]: TLC (ethyl acetate/hexane 1:1): Rf = 0.80. 1H NMR 
(500 MHz, CDCl3): δ 8.84 (bs, 1H), 7.77 (d, 1H), 7.54-7.52 (m, 6H), 7.33-7.15 (m, 25H),  6.54-
6.52 (m, 1H, H-1’), 4.55-4.52 (m, 1H, H-2’), 4.01 (s, 1H), 3.21-3.18 (m, 1H, H-5’/H-5’’), 3.08-
 
  
 
 
 
 
 
3.06 (m, 1H, H-5’/H-5’’),  2.88 (d, 1H, H-3’). 13C NMR (125MHz, CDCl3): δ 149.3, 143.1 
(CO), 142.7 (CO), 138.9, 128.6, 128.4, 128.3, 128.0, 127.9, 127.5, 88.1 (quat. C), 88.0 (quat. 
C), 86.7 (C1’), 84.5 (C4’), 77.7 (C2’), 70.9 (C3’), 64.2 (C5’). HRMS (EI+): m/z for 
[C47H39FN2O6Na]+ calcd. 769.2684; found 769.2693. 
4.3. General procedure for introducing benzhydryl moieties 
To a solution of the respective nucleoside (100 mg) and diphenylmethanol in dichloroethane (5 
mL/mmol) was added palladium chloride (0.2 eq).  The reaction mixture was heated at 85 °C 
under Argon atmosphere for 16 h or until disappearance of the starting materials. The reaction 
was monitored by TLC.  The solvent was removed in vacuo and the crude mixture obtained 
was purified by column chromatography to afford the desired compound. Analytical details for 
the different compounds obtained can be found in reference[15]. 
4.4. Antiviral and toxicity assay for DENV 
Green monkey kidney cells [Vero-B ECACC] were grown in minimum essential medium MEM Rega-
3 (Gibco, Merelbeke, Belgium) supplemented with 10% foetal calf serum (FCS), 1% L-glutamine and 
1% sodium bicarbonate. Vero-B cells were seeded at a density 7 x 10
3
 cells/well in 100 μl assay medium 
and allowed to adhere overnight.  Antiviral assays were performed in medium supplemented with 2% 
FCS, 1% L-glutamine and 1% sodium bicarbonate. After washing cells twice with 2% FCS  medium, 
serial compound dilutions (1:2) were added to each well (starting concentration 100 µg/mL), followed 
by adding 100 μl of 2% PBS culture medium containing 100 µL  50% cell culture infectious doses (i.e., 
CCID50) of virus. 
 
  
 
 
 
 
 
After 7 days of incubation, the FCS culture medium was discarded and cells were fixed with ethanol 
and stained with 1% methylene blue, and EC50 and CC50 were determined visually.  The 50% effective 
concentration (EC50) is defined as the compound concentration that is required to inhibit the virus-
induced CPE by 50%, and 50% cytotoxic concentration (CC50) is defined as the compound 
concentration that is required to inhibit the cell growth by 50%. 3’,5’ di-O-trityluridine (initial hit) and 
ribavirin were included as reference compounds. 
4.5. Antiviral and toxicity assay for YF17D 
Green monkey kidney cells [Vero-B ATCC CCL-81] were grown in minimum essential medium MEM 
Rega-3 (Gibco, Merelbeke, Belgium) supplemented with 10% foetal calf serum (FCS), 1% L-glutamine 
and 1% sodium bicarbonate. Vero-B cells were seeded at a density of 2 x 10
4
 cells/well in 100 μl assay 
medium and allowed to adhere overnight.  Antiviral assays were performed in medium supplemented 
with 2% FCS, 1% L-glutamine and 1% sodium bicarbonate. After washing cells twice with 2% FCS 
medium, serial compound dilutions (1:2) were added to each well (starting concentration 50 µg/mL), 
followed by adding 100 μl of 2% PBS culture medium containing 100 µL  50% cell culture infectious 
doses (i.e., CCID50) of virus.  After 7 days of incubation, 2% FCS culture medium was discarded 
and cells were fixed with ethanol and stained with 1% methylene blue, and EC50 and CC50 were 
determined visually as for DENV. 
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 DENV YFV EC50 CC50 SI EC50 CC50 SI 
 Uridine analogues 
5’-trityl11 6 10 1.67 4 18 4.5 
2’,5’-trityl11 (2) 30 >100 > 3 1.2 >100 >80 
2’,5’-Bnh (44) >50 3.7 0.07 >50 2.4 - 
3’,5’-trityl11 (1) 1.75 >10 >6 1 >85 >85 
3’,5’-Bnh (45) 1.23 1.85 1.5 >50 >50 1.0 
2’,3’,5’-Bnh (46) >50 33.3 0.67 >50 2.4 - 
 5-Fluorouridine derivatives 
5’-trityl (41) >50 8.15(±2.05) <0.16 >50 9.0 (±0.9) >0.18 
2’,5’-trityl (42) >50 9.6 <0.2 1.1 29.0 27 
2’,5’-Bnh (47) >50 1.23 0.02 1.15 1.16 1.0 
3’,5’-trityl (43) 3.4 6.7 2 0.425(±0.1) 4.38 (±1.7) 10.3 
3’,5’-Bnh (48) 1.23 3.7 3 >50 2.8 - 
2’,3’,5’-Bnh (49) 11.1 5.56 0.5 4 >50 >12.5 
 2’-deoxyuridine congeners 
5’-trityl11 ND 8 - 3 5 1.7 
3’,5’-trityl11 3.7 >65 >17 0.9 >65 >70 
3’,5’-Bnh (50) >50 1.23 0.02 >50 1.07 - 
 5-Fluoro 2’-deoxyuridine derivatives 
5’-trityl (38) >50 4.6 <0.1 >50 6.9(±3.9) <0.14 
3’,5’-trityl (39) 1.2 >50 >41 1.05(±0.42) >50 >47 
3’,5’-Bnh (51) >50 3.7  >50 1.85 - 
 Thymidine series 
5’-trityl (17) 4 4 1 ND 8  
5’-benzyl (23) >100 >100 1 >100 >100 - 
3’,5’-trityl (21) ND 35  10 70 7 
3’,5’-Bnh (52) >50 1.23 0.02 >50 1.5 - 
3’,5’-benzyl (24) >100 18.75 <0.19 >100 37.5 <0.37 
 N3-methyl thymidine analogues 
5’-trityl (6) ND 5  5 5 1 
5’-benzyl (15) ND 60  ND 70  
3’,5’-trityl (10) >100 >100 1 >100 >100 1 
3’,5’-benzyl (14) ND 8  ND 12  
 Reference compounds 
2CMC 2.57 (±0.5) (10 µM) 
>15 
(>50 µM) >5 ND ND  
T705 ND ND  25  (157 µM) 
>385 
(>2.4 mM) >15 
Ivermectin >1 µM 3.8 µM  ± 5 nanoM 3.5 µM ± 700 
 
Table 1.  Antiviral activity assessment of some tritylated, diphenylmethylated and benzylated 
nucleoside analogues versus Dengue virus and yellow fever virus, determined as described in 
the Materials and Methods section (values expressed in microgram/mL unless indicated). Bnh 
 
  
 
 
 
 
 
is used as abbreviation for the benzhydryl (diphenylmethyl) group. Activities for some 
compounds were reported before, see [11]. 
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Fig. 1. Structure of the lead compound 1 and its antiviral active analogues 2 and 3.  
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17 R3= Tr, R4= H
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21 R3= R4= Tr
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24 R3= R4= Benzyl
25 R3= Fmoc, R4= H
26 R3= R4= Fmoc
27 R3= COAd, R4= H
28 R3= R4= COAd
29 R3= R4= Ac
30 R3= R4= TBDMSi
31 R3= R4= TIPSi
32 R3= R4= TBDPSi
33 R3= R4= TBPMethoxySi
6 R1= Tr, R2= H
7 R1= Benzoyl, R2= H
8 R1= Benzoyl, R2= Tr
9 R1= H, R2= Tr
10 R1= R2= Tr
11 R1= R2= Me
12 R1= C12H25, R2= H
13 R1= R2= C12H25
14 R1= R2= Benzyl
15 R1= Benzyl, R2= H
16 R1= H, R2= Benzyl
6-16
17-33
K2CO3, DMF,
Methyl Iodide
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Fig. 2.  Synthesis of different 3' or 5' modified or bis-modified thymidine analogues.  Reaction 
conditions: i) either 1.2 or 2.5 eq of TrCl, pyridine, 85 °C, 16-18 h; ii) 1.2 eq BzCl, pyridine, rt, 
2 h; iii) LiOH, MeOH:H2O (1:1), rt, 18 h; iv) NaH, MeI, dry DMF, rt, 45 min; v) NaH, 
C12H25Br, either 1.1 or 2.2 eq, dry DMF, rt, 2 h; vi) 2.2 eq of NaH, 2.5 eq BnBr, dry DMF, rt, 
2 h; vii) NaH, BnBr, 1.1 eq each, dry DMF, 0 °C, 4 h; viii) 2.2 eq NaH, 2.5 eq BnBr, dry THF, 
50 °C; ix) 80% aq AcOH, 50 °C, 1 h; x) either 1.2 or 2.5 eq of FmocCl, pyridine, rt, 18 h; xi) 
2.2 eq AdamantylCl, pyridine, 70 °C, 18 h; xii) 2.2 eq of AcCl, ACN, TEA, DMAP, 5 h; xiii) 
3 eq of t-butyldimethylsilyl chloride (TBDMSiCl), imidazole, dry DMF, rt, 18 h; xiv) 3 eq 
triisopropylsilyl chloride (TIPSiCl), imidazole, dry DMF, rt, 18 h; xv) 3 eq t-butyldiphenylsilyl 
 
  
 
 
 
 
 
chloride (TBDPSiCl), imidazole, dry DMF, rt, 18 h; xvi) 3 eq t-butylphenylmethoxysilyl 
bromide (TBPMethoxySiBr), imidazole, dry DMF, rt, 18h. 
Synthesis starting from 5: for 6: i using 1.2 eq; 7: ii; 8: ii, i; 9: ii, i, iii; 10: i using 2.5 eq; 11: iv; 
12: v; 13: v; 14: vi; 15 and 16: vii  
Synthesis starting from 4: 17: i; 18: ii; 19: ii, i; 20: ii, i, iii; 21: i; 22: i, viii; 23: i, viii, ix; 24: 
viii; 25 and 26: x ; 27 and 28: xi; 29: xii; 30: xiii; 31: xiv; 32: xv; 33: xvi.  
 
  
 
 
 
 
 
O
OR2
R1O
N
NH
O
O
F
O
OH
HO
N
NH
O
O
F
O
OHOH
HO
N
NH
O
O
F
O
OR3OR2
R1O
N
NH
O
O
F
38 R1= Tr, R2= H
39 R1= R2=  Tr
37
40 41 R1= Tr, R2= H, R3= H
42 R1= R2= Tr, R3= H
43 R1= R3= Tr, R2= H
i
i
 
 
Fig. 3. Synthesis of tritylated derivatives of 5-fluoro-2'-deoxyuridine and 5-fluorouridine. 
Reaction conditions: i) either 1.2 or 2.5 eq of triphenylmethyl chloride, pyridine, 85 °C, 16 h. 
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Fig. 4.  Attempted synthesis of O4-methyl -3',5'-bistritylthymidine. Reaction conditions: i) a) 
TEA, TMSCl, ACN, rt, 1.5 h; b) 1H-triazole, POCl3, 0 °C, 5 h; ii) NaOMe, MeOH, rt, 30 min; 
iii) 2.5 eq TrCl, pyridine, 85 °C, 18 h. 
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Fig. 5.  Introduction of benzhydryl moieties on some selected ribonucleosides and 2'-
deoxyribonucleosides 
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